Pituitary, Thyroid & Adrenal Disorders
From the Journals
Cancer risk after radioiodine for hyperthyroidism ‘small’: Meta-analysis
Studies showing a linear dose-response risk warrant further research, but overall assessment of risks called “reassuring.”
From the Journals
When should patients with kidney disease receive nephrology referral?
Combining predicted kidney failure risk with lab values will lead to better patient outcomes, according to the author of a new paper.
From the Journals
Vitamin D pills do not alter kidney function in prediabetes
A subgroup analysis suggests Vitamin D supplements could have a beneficial effect on kidney health.
From the Journals
Levothyroxine overprescribing common, consistent over time
A study detailing the consistent overuse of the thyroid replacement drug over a decade should be a “call to action” for doctors to stop treating...
Conference Coverage
What’s behind brain fog in treated hypothyroidism?
A large survey is believed to be the first to explore the common phenomenon and identify potential avenues of treatment.
Conference Coverage
Daily cup of coffee cuts type 2 diabetes risk by about 5%
Beneficial effects may be caused by coffee’s ability to reduce inflammation.
From the Journals
Mild cortisol excess increases mortality in adrenal incidentaloma
Autonomous cortisol secretion level following dexamethasone suppression test in patients with adrenal incidentalomas, but without Cushing syndrome...
Conference Coverage
Two treatments show early promise for hypothalamic obesity
News
Acella recalls NP Thyroid lots found to have reduced potency
The voluntary recall of the desiccated thyroid product is the third in a year due to potency issues.
Conference Coverage
Cushing’s death rate ‘unacceptable,’ triple that of general population
Death rates among patients with endogenous Cushing’s syndrome have dropped since 2000 but are still threefold that of the general population.
Conference Coverage
In low-risk thyroid cancer, no advantage found for postsurgical iodine
Forgoing postoperative radioactive iodine in low-risk differentiated thyroid cancer is supported by phase 3 data.